2.
    发明专利
    未知

    公开(公告)号:DE10163215A1

    公开(公告)日:2003-07-10

    申请号:DE10163215

    申请日:2001-12-21

    Abstract: An image system, notably an X-ray system and an ultrasound system, is provided in which images or sequences of images are generated and used to automatically change or optimize the operational behavior of individual image system components. Measurement fields are defined in the images of an image sequence by means of a data processing unit. Information is extracted from the measurement fields in order to adapt the system components. More specifically, in the course of a sequence of images the measurement fields are adapted or shifted in conformity with the motion of objects.

    DEVICE AND METHOD FOR DETERMINING THE CONCENTRATION OF A TRACER IN BLOOD
    3.
    发明申请
    DEVICE AND METHOD FOR DETERMINING THE CONCENTRATION OF A TRACER IN BLOOD 审中-公开
    用于确定血中示踪剂浓度的装置和方法

    公开(公告)号:WO2005044311A2

    公开(公告)日:2005-05-19

    申请号:PCT/IB2004052299

    申请日:2004-11-04

    Inventor: BRAESS HENNING

    CPC classification number: A61B6/481 A61B5/02755 A61B6/03 A61B6/037 A61B6/507

    Abstract: The invention relates to device and a method for determining the concentration of a PET tracer in the blood of a patient (1). With the aid of an X-ray CT (5, 6), first of all the spatial position (r) of a volume element (2) that is filled with blood is determined, which for example can be a part of the aorta or of the left ventricle of the heart. Subsequently, a TOF­ PET unit that comprises two detector elements (3a, 3b) is set in such a way that it establishes the concentration of the tracer in this volume element (2) and thus in the blood. This value can for example be used within the framework of pharmaco-kinetic examinations which are carried out on the patient (1) with the aid of a three-dimensional PET unit (4).

    Abstract translation: 本发明涉及用于确定患者血液中PET示踪剂浓度的装置和方法(1)。 借助于X射线CT(5,6),首先确定充满血液的体积元件(2)的空间位置(r),其例如可以是主动脉的一部分或者 心脏的左心室。 随后,设置包括两个检测器元件(3a,3b)的TOF PET单元,使得其建立该体积元件(2)中的示踪剂浓度并因此确定血液中的示踪剂浓度。 这个值可以在例如在患者(1)上借助于三维PET单元(4)进行的药物动力学检查的框架内使用。

Patent Agency Ranking